Non-Invasive Biomarkers For NASH Drug Development

Posted: March 31, 2021

It’s Not Just Support. It’s Solutions.

 

Biomarker Assays for Fatty Liver Disease Clinical Trials

 

Cytokeratin 18 (CK18/ccCK18/K18)

Include M30 Apoptosense® (ccCK18) and M65® ELISA (CK18) as part of your mechanistic biomarker panel to get a fuller picture of effects of your drug candidate.

The Problem Liver biopsies are not always practical; slow and cost is high. Lack of biomarkers that accurately (low specificity) reflect extent of liver injury History of contributing to failed or delayed trials	The Solution Better data for more informed decisions Collect data on multiple biomarker readouts Mechanistic serum biomarkers to reflect changes in histology Specific hepatocyte cell death and fibrosis biomarkers

 

The Advantages

• Determine ongoing disease activity
• Early indication of drug efficacy
• Reduce biopsies in clinical trials
• Simpler and quantitative assays
• Provide supplementary information to traditional biomarkers

 

Specializing in Mechanistic Biomarkers
NAFLD/NASH	ALD/AH	DILI Research	K18: M30®/M65®

Explore our full portfolio of assays.
Help your drug candidate move forward.

 

DiaPharma offers:
Collagen IV • L-FABP • FGF-19 • FGF-21 • Fibronectin • hsCRP • Mac-2-BP • Noggin • NGAL • Osteopontin • PAI-1 • sCD163 • and more

Research use only in the U.S. and Canada. Not for use in diagnostic procedures.

 

It’s Not Just Support. It’s Solutions. If you’d like to speak with an expert about which biomarker would be most useful for your project, our scientific and customer support teams are just a call or click away.

Copyright © 2021 DiaPharma Group, Inc. All rights reserved. Our mailing address is: DiaPharma Group, Inc., 8948 Beckett Rd., West Chester, OH 45069 USA ML-00-00786Rev01